Investors Overview

Corporate Profile

Bacterin International Holdings, Inc., Belgrade, MT (NYSE: BONE), a developer of bioactive coatings for medical applications and revolutionary bone graft material, processes and markets innovative, biologic allografts for transplantation. The Company’s biologic scaffolds, OsteoSponge®, OsteoSponge® SC and OsteoWrap®, are made from demineralized bone that is malleable and flexible, which enables more efficient and precise handling. It also markets BacFast® and OsteoLock®, which are used in ...
More

Stock Quote
BONE (Common Stock)
ExchangeNYSE (US Dollar)
Price$0.70
Change (%)0.00 (0.00%)
Volume214,931
Data as of 04/17/14 3:55 p.m. ET
Minimum 20 minute delay
Refresh quote
Stock Chart
Stock chart for: 03NA000000BONE
Recent News
DateTitle 
04/08/14Bacterin Announces the Addition of Two Vice Presidents
BELGRADE, Mont.--(BUSINESS WIRE)--Apr. 8, 2014-- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, is pleased to announce the addition of Jimmy Bornheimer, Vice President of Finance, and Stephen Smith, Vice President of Regulatory and Quality Assurance. Both Mr. Bornheimer and Mr. Smith bring vast experience in their fields and fill new positions... 
Printer Friendly Version
03/20/14Clinical Results on the Use of Bacterin’s OsteoSponge® for Foot and Ankle Arthrodeses Procedures Published in Orthopedics Today
BELGRADE, Mont.--(BUSINESS WIRE)--Mar. 20, 2014-- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft materials and bioactive coatings for medical applications, announces that results utilizing OsteoSponge® bone graft for foot and ankle arthrodeses procedures has been published in the peer-reviewed journal Orthopedics. This is the second publication for Bacterin that highlights clinical outcomes... 
Printer Friendly Version
03/19/14Bacterin Announces Full Year 2013 Results
BELGRADE, Mont.--(BUSINESS WIRE)--Mar. 19, 2014-- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and coatings for medical applications, today reported financial results for the fourth quarter and full year ended December 31, 2013. The Company reported annual revenues of approximately $33.1 million and a net loss for the year of approximately $12.7 million, or ($.27) per common shar... 
Printer Friendly Version
03/13/14Bacterin Announces the Launch of OsteoSTX, a Novel Biologic Product
BELGRADE, Mont.--(BUSINESS WIRE)--Mar. 13, 2014-- Bacterin International Holdings, Inc. (NYSE MKT: BONE) is pleased to announce the launch of OsteoSTX, a new novel allograft for orthopedic procedures. Utilizing Bacterin’s proprietary demineralization technology, OsteoSTX are flexible cortical DBM matchsticks designed for multli-level and deformity spinal applications. “This is the first product Bacterin has launched since I joined the Comp... 
Printer Friendly Version
More

Upcoming Events
There are currently no events scheduled.
More

Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Bacterin International Holdings Inc posts new information to the site. Just enter your e-mail address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.